Five-year overall survival (OS) and OS by baseline liver function from the Phase 3 HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC) - Wirth, T; Kudo, M; Rimassa, L; Chan, S L; Sangro, B; Lau, G; Breder, V; Varela, M; Crysler, O V; Bouattour, M; Dao, T V; Faccio, A; Furuse, J; Jeng, L-B; Kang, Y-K; Kelley, R K; Paskow, M J; Makowsky, M; Ran, D; Negro, A; Abou-Alfa, G K (Zeitschrift für Gastroenterologie, 2025)